

SARS-CoV-2 Variant Evaluation Statement

We as, Vitrosens Biyoteknoloji Ltd. Şti, located in Şerifali Mah. Şehit Sk. No: 17, 34775, Ümraniye/İstanbul, Turkey which is a high-tech manufacturing facility in Turkey that integrated R&D, production, and sales; we became a reliable manufacturer of the Covid-19 rapid diagnostic test kit.

As the new variant emerges, it concerns the world that the new variant has many mutations, and its transmissibility is still unknown.

As a result of the analysis, we declare that our “RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) (VSCD02ST)” product is not affected by the mutations of the listed variants by staying outside the target detection region of the test and the product can detect SARS-CoV-2 virus with high sensitivity.

WHO Label	Pango Lineage
Omicron	B.1.1.529 BA.2 BA.4 BA.5
Alpha	B.1.1.7
Beta	B.1.351
Gamma	P.1
Delta	B.1.617.2
Lambda	C.37
Mu	B.1.621
Eta	B.1.525

As usual, we will be bringing you more as the variants develop and we will keep our database updated and focus on evaluating the detection ability of our kit against SARS-CoV-2 variants, maintain its sensitivity and specificity.

Date of issue: 20.06.2022

Place of issue: İstanbul



VITROSENS
BIOTECHNOLOGY
VITROSENS BIYOTEKNOLOJİ LİMİTED ŞİRKETİ
Serifali Mah. Şehit Sk. No: 17/1, Ümraniye/İST
Sarıgazi V.D. 921 096 0962 Sicil No: 279270-5
www.vitrosens.com info@vitrosens.com
Kağan Erka YÖRÜK
General Manager